Barely Significant
← all excerpts

Immunotherapy in nasopharyngeal carcinoma: current status and unanswered questions.

Lancet Reg Health West Pac · 2025 · PMC12000728 · PMID 40242461

Europe PMCDOI
1
hedged sentence
0.2262
closest p · 4.5× alpha
0.2262
boldest claim

The sentences

a favorable trendp = 0.2262not close (p > 0.1)
In contrast, the KEYNOTE-122 trial, which investigated pembrolizumab asmonotherapy in patients with recurrent or metastatic NPC who had previously failed platinum-based chemotherapy, did not report a significant improvement in OS in the pembrolizumab arm, despite showing a favorable trend (HR 0.9, 95% CI: 0.67–1.19, p = 0.2262).

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.